Capsida Bio is a startup based in the United States, 1 tracked investor.
Capsida Bio is a company founded in 2019 headquartered in the United States. Brouky records 1 investor associated with the company.
Capsida Bio engineers novel adeno-associated viruses (AAVs) and develops targeted gene therapies for neurological and ocular diseases using advanced capsid engineering and preclinical screening technologies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.